ConductScience.org, home
Papers
API referenceFor AI assistants

Paper26625317

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.

Airiau K and 9 others. Oncotarget, 2016. Cited by 18 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells. Papers, record 26625317. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26625317

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
PubMed
Journal
Oncotarget
PubMed
Year
2016
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.49
iCite
Revised in PubMed
2018-11-13
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Airiau KKelly
2Prouzet-Mauléon VValérie
3Rousseau BBenoit
4Pigneux AArnaud
5Jeanneteau MMarie
6Giraudon MManon
7Allou KKaoutar
8Dubus PPierre
9Belloc FFrancis
10Mahon FXFrançois-Xavier

Source PubMed

Topics26

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aniline CompoundsMajor topic
ApoptosisMajor topic
Cell ProliferationMajor topic
MAP Kinase Kinase 1Major topic
MAP Kinase Kinase 2Major topic
NiacinamideMajor topic
SulfonamidesMajor topic
Acute Disease
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Cell Line, Tumor
Cell Survival
Drug Synergism
G1 Phase Cell Cycle Checkpoints
HL-60 Cells
Humans
Immunohistochemistry
Leukemia, Myeloid
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Protein Kinase Inhibitors
Tumor Burden
U937 Cells
Xenograft Model Antitumor Assays

Source PubMed

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119,463,767Acute myelogenous leukemia.Exp Hematol2009https://conductscience.org/library/papers/19463767PubMed
219,008,455Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.Blood2009https://conductscience.org/library/papers/19008455PubMed
320,581,309
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Blood2010https://conductscience.org/library/papers/20581309PubMed
421,628,402The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.Blood2011https://conductscience.org/library/papers/21628402PubMed
522,064,351MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.Leukemia2012https://conductscience.org/library/papers/22064351PubMed
622,240,609ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.Exp Hematol2012https://conductscience.org/library/papers/22240609PubMed
722,496,272Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res2012https://conductscience.org/library/papers/22496272PubMed
822,624,727Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.Br J Pharmacol2012https://conductscience.org/library/papers/22624727PubMed
923,333,149BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.Cell Stem Cell2013https://conductscience.org/library/papers/23333149PubMed
1023,398,943The MYB oncogene can suppress apoptosis in acute myeloid leukemia cells by transcriptional repression of DRAK2 expression.Leuk Res2013https://conductscience.org/library/papers/23398943PubMed
1123,587,417MEK and the inhibitors: from bench to bedside.J Hematol Oncol2013https://conductscience.org/library/papers/23587417PubMed
1223,629,727
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Int J Cancer2013https://conductscience.org/library/papers/23629727PubMed
1324,178,622Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Clin Cancer Res2014https://conductscience.org/library/papers/24178622PubMed
1424,346,116Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Cancer Discov2014https://conductscience.org/library/papers/24346116PubMed
1511,021,753The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.Leukemia2000https://conductscience.org/library/papers/11021753PubMed
1611,090,080The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.Blood2000https://conductscience.org/library/papers/11090080PubMed
1711,031,257
Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1).
J Biol Chem2001https://conductscience.org/library/papers/11031257PubMed
1811,560,954Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.J Clin Invest2001https://conductscience.org/library/papers/11560954PubMed
1912,209,154The Bcl2 family: regulators of the cellular life-or-death switch.Nat Rev Cancer2002https://conductscience.org/library/papers/12209154PubMed
2014,555,991Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.Oncogene2003https://conductscience.org/library/papers/14555991PubMed

See all 38 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
38,946,802Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells.Front Cell Dev Biol2024https://conductscience.org/library/papers/38946802PubMed
38,831,555A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling.Cancer Med2020https://conductscience.org/library/papers/38831555PubMed
36,518,303Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemia.Front Oncol2022https://conductscience.org/library/papers/36518303PubMed
34,203,664Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia.Antioxidants (Basel)2021https://conductscience.org/library/papers/34203664PubMed
33,214,852Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines.Trop Life Sci Res2020https://conductscience.org/library/papers/33214852PubMed
31,717,784Targeting Apoptotic Pathways in Acute Myeloid Leukaemia.Cancers (Basel)2019https://conductscience.org/library/papers/31717784PubMed
31,645,898PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors.Oncotarget2019https://conductscience.org/library/papers/31645898PubMed
31,123,034Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.Haematologica2020https://conductscience.org/library/papers/31123034PubMed
29,580,266Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.BMC Res Notes2018https://conductscience.org/library/papers/29580266PubMed
29,488,172Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.Eur J Drug Metab Pharmacokinet2018https://conductscience.org/library/papers/29488172PubMed
29,398,802Inducing Apoptosis and Decreasing Cell Proliferation in Human Acute Promyelocytic Leukemia Through Regulation Expression of CASP3 by Let-7a-5p Blockage.Indian J Hematol Blood Transfus2018https://conductscience.org/library/papers/29398802PubMed
29,146,569Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Cancer Discov2017https://conductscience.org/library/papers/29146569PubMed
27,618,887Arctigenin Inhibits Lung Metastasis of Colorectal Cancer by Regulating Cell Viability and Metastatic Phenotypes.Molecules2016https://conductscience.org/library/papers/27618887PubMed

Genes31

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
BAK1578PubTator's text mininghttps://conductscience.org/library/genes/578NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BBC327,113PubTator's text mininghttps://conductscience.org/library/genes/27113NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
BCL2L1110,018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
CASP3836PubTator's text mininghttps://conductscience.org/library/genes/836NCBI Gene
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CDKN1A1,026PubTator's text mininghttps://conductscience.org/library/genes/1026NCBI Gene
CDKN1B1,027PubTator's text mininghttps://conductscience.org/library/genes/1027NCBI Gene
CSF21,437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
EPO2,056PubTator's text mininghttps://conductscience.org/library/genes/2056NCBI Gene
FLT12,321PubTator's text mininghttps://conductscience.org/library/genes/2321NCBI Gene
FLT32,322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
IL33,562PubTator's text mininghttps://conductscience.org/library/genes/3562NCBI Gene
IL3RA3,563PubTator's text mininghttps://conductscience.org/library/genes/3563NCBI Gene
IL63,569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
KITLG4,254PubTator's text mininghttps://conductscience.org/library/genes/4254NCBI Gene

See all 31 genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26625317

GET https://conductscience.org/api/papers/v1/26625317/references?page=2

API referenceFor AI assistants